ADCT (ADC Therapeutics) PB Ratio: (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADCT ADC Therapeutics SA ADCT
41 GF Score
Price $1.28
GF Value $2.09
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is ADC Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-21), ADC Therapeutics's share price is $1.275. ADC Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was $-1.70. Hence, ADC Therapeutics's PB Ratio of today is .

The historical rank and industry rank for ADC Therapeutics's PB Ratio or its related term are showing as below:

During the past 10 years, ADC Therapeutics's highest PB Ratio was 12.07. The lowest was 1.95. And the median was 5.37.

ADCT's PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.86
* Ranked among companies with meaningful PB Ratio only.

During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of ADC Therapeutics was 8.70% per year. The lowest was -13.40% per year. And the median was 0.15% per year.

Back to Basics: PB Ratio


ADC Therapeutics  (NYSE:ADCT) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


ADC Therapeutics PB Ratio Related Terms


ADC Therapeutics PB Ratio Historical Data

* Premium members only.

The historical data trend for ADC Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADC Therapeutics PB Ratio Chart

ADC Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.34 3.90 0.00 0.00 0.00

ADC Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ADCT vs GNLX, VXRT, COYA: PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, ADC Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ADC Therapeutics PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ADC Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where ADC Therapeutics's PB Ratio falls into.


ADCT
41GF Score
ADC Therapeutics SA ADCT
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ADC Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

ADC Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=1.275/-1.702
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is ADC Therapeutics (ADCT) Overvalued in 2026?

Based on GuruFocus' analysis, ADC Therapeutics stock appears to be undervalued. The current stock price of $1.28 is trading 39% below its estimated GF Value™ of $2.09. GuruFocus considers ADC Therapeutics to be Possible Value Trap.

Key valuation signals for ADCT:

  • PB Ratio:
  • GF Value™: $2.09 vs. price of $1.28 (39% below fair value)
  • GF Score™: 41/100 with 5 warning signs

No single metric tells the full story. See the ADCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ADC Therapeutics Business Description

Address Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
41GF Score

Get the complete analysis for ADCT

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.28
Price
$2.09
GF Value